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WHILE a considerable amount of research has been undertaken in attempts to
demonstrate an incidence relationship between diabetes mellitus and cancer,
scant attention has been paid to the influence of the diabetic state on malignant
disease. In particular, no information is available on how the diabetic patient
with cancer fares when compared with his non-diabetic counterpart in terms of
survival, rate ofgrowth ofprimary tumours and secondary tumour development.
The present experimental investigation, which uses rats as the test animals,
was undertaken to determine the influence of alloxan induced diabetes on solid
tumour growth rates and to estimate the effect of alloxan diabetes on the metas-
tatic potential of circulating cancer cells. The influence of malignant disease on
diabetes was also investigated.
EXPERIMENTAL METHODS
Female albino Sprague-Dawley rats obtained from the Oxfordshire Laboratory
Animal Colonies were used. They weighed between 200-240 g. at the beginning
of the experiment and were approximately 8 weeks old.
Diabetes was induced by repeated intraperitoneal injections of small amounts
of alloxan monohydrate (Hopkin and Williams, Ltd.) following the method
described by Caridis, Blair, Kilpatrick and Carr (1966). The criteria set forth by
these authors for accepting rats into the diabetic group were used. Throughout
the experiment these rats were fed a standard cubed diet and drinking water was
supplied ad libitum in the form of a 2-5 per cent dextrose solution.
The experimental tumour system used in this investigation was the Walker
256 rat carcinosarcoma. It was prepared in the form of a sterile suspension of
single tumour cells in Hank's balanced salt solution using a modification of the
method described by Rodin, Turner and Couves (1963). The final concentration
of this freshly prepared suspension was adjusted to contain 5000 viable tumour
cells per 041 ml. of solution.
The rats were divided into 3 groups.
Group 1.-There were 10 rats in this group. They received no treatment other
than injections of alloxan monohydrate intraperitoneally. They were retained
for 16 days following the last intraperitoneal injection. At this stage they were
rendered unconscious by ether anaesthetic and killed by exsanguination following
cardiac puncture. The rats had been deprived of food and drinking water in the
12 hours immediately preceding death. The sugar concentration of the blood
removed by cardiac puncture was determined byNelson's modification ofSomogy's
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Group 2.-A total of 41 rats were used. Twenty animals made up a control
group and these animals were given intraperitoneal injections of sterile water in
place of alloxan monohydrate. The control rats were maintained on a standard
cubed diet and water was supplied ad libitum. The remaining 21 rats were
treated with intraperitoneal alloxan monohydrate and formed the test group.
Forty-eight hours after the last intraperitoneal injection all the rats had the left
hind limb shaved and following cleaning of the overlying skin all the animals in
the control group and the test group were given an intramuscular injection of
0.1 ml. of the freshly prepared tumour cell suspension into the posterior thigh
muscle. Fourteen days after the intramuscular cell injections all the animals were
rendered unconscious by ether anaesthetic and immediately killed by exsanguina-
tion following cardiac puncture. Food and drinking water had been withdrawn
12 hours before death. The hind limb tumours were exposed by removing the
overlying skin and surrounding muscle and the maximum diameter of each limb
tumour was estimated using a measuring calliper. The blood sugar level at the
time of death was determined.
Group 3.-There were 41 rats in this group. As in the previous experiment a
control group of 20 rats maintained on a standard cubed diet with drinking water
supplied ad libiturn, received injections of distilled water intraperitoneally. A
test group of 21 rats was treated with intraperitoneal alloxan monohydrate.
In this experiment the freshly prepared tumour cells were " aged " under
aseptic conditions for 12 hours at room temperature after the method described by
Chan, Hadden, McDonald and Cole (1961). Their experimental results indicate
that " aging " cancer cells for 6 to 12 hours will reduce the percentage oftumours
produced following cell injection to a level somewhere between 60 and 30 per
cent. This technique is of great value when it is not known whether a certain
procedure or substance will increase or decrease the development oftumours after
inoculation of cancer cells.
All the rats in the test and control groups were given a single intravenous
injection of 0 1 ml. of the " aged " tumour cell suspension into the exposed
saphenous vein found on the inner aspect of the hind limb 48 hours after the last
intraperitoneal injection. The cells were injected under ether anaesthesia. The
animals were retained for 14 days after the intravenous cell injections and were
then killed by exsanguination following cardiac puncture under ether anaesthetic.
As with the previous groups, food and drinking water was withdrawn 12 hours
before death. They were subjected to careful post-mortem examinations to
determine the presence of tumours. Macroscopic appearances were noted and
selected tissues were excised for microscopic study. The blood sugar level at the
time of death was determined.
RESULTS
All the rats in the three groups remained in good condition throughout the
duration of the experiment. It was noticeable, however, that the food and fluid
intake of the alloxan diabetic rats was in excess of that of the non-diabetic
animals.
The mean blood sugar value for the 10 rats in group 1 at the time of death
was 230 mg. per cent with a standard deviation of 33 mg. per cent.
The experimental findings for group 2 are shown in Table I. The developing
limb tumours were all palpable in the non-diabetic control rats 6 days after the
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TABLE I.-The Effect of Alloxan Induced Diabetes on Solid Tumour Growth Rate
and the Effect of Developing Solid Limb Tumours on the Blood Sugar Level of
Alloxan Diabetic Rats. Recordings made After 14 Days of Tumour Growth
Number Mean maximum tumour
of diameter ± S.D. Mean blood sugar + S.D.
rats (mm.) (mg.%)
Control Group . 20 . 36±8-7 . 96+15
Alloxan diabetic group . 21 . 20±3-5 . 160±28
intramuscular tumour cell injections. In the diabetic group all the developing
limb tumours were palpable 8 days after the cell injections. At the time ofdeath
the mean maximum tumour diameter for the non-diabetic animals was 36 mm.
The mean maximum diameter for the alloxan diabetic group ofanimals was found
to be significantly less at 20 mm. The mean blood sugar value for the non-
diabetic control group ofrats was 96 mg. per cent at the time ofdeath. The normal
range of blood sugar values for untreated rats in our laboratory when killed,
following 12 hours deprivation offood and drinking water, is 75-100 mg. per cent.
The mean blood sugar value for the alloxan diabetic, tumour bearing, rats at the
time of death was 160 mg. per cent. While this blood sugar value is greater than
that the mean blood sugar value for the non-diabetic tumour bearing animals, it is
less than the mean blood sugar value determined for the alloxan diabetic, but
non-tumour bearing, group of rats (group 1).
TABLE II.-The Effect of Alloxan Induced Diabetes on the Development of Tumour
Metastasesfrom Circulating Cancer Cells and the Effect ofthe TumourMetastases
on the Blood Sugar Level of Alloxan Diabetic Rats. Recordings made 14 Days
After the Intravenous Injection of Cancer Cells.
Metastases present Metastases absent
A A
Number Number Mean blood Number Mean blood
of of sugar ± S.D. of sugar + S.D.
rats rats (mg.%) rats (mg.%)
Control group . . . 20 . 11 87±12 . 9 76±11
Alloxan diabetic group . 21 . 5 103±12 16 210±42
The experimental results for group 3 are shown in Table II. Pulmonary
deposits of the Walker 256 tumour were found in 11 of the 20 rats in the non-
diabetic control group at post-mortem examination. Five of the 21 rats in the
diabetic group has tumour deposits within the lungs. These figures represent
the findings on both macroscopic and microscopic examination of the lungs. In
the diabetic group of animals the pulmonary tumours were smaller and more
discrete than in the non-diabetic animals. In neither the control group nor the
test group were tumour deposits found at any site other than the lungs. There
was, therefore, a 55 per cent positive tumour take in the non-diabetic rats and a
24 per cent positive tumour take in the diabetic rats. The mean blood sugar
value at the time of death in the 11 non-diabetic rats with pulmonary metastases
was within normal limits at 87 mg. per cent. The mean blood sugar value for
the 5 diabetic rats with pulmonary metastases was slightly elevated at 103 mg.
per cent. The mean blood sugar value for the 9 rats in the control group that
failed to develop tumour metastases from the circulating cancer cells was 76 mg.
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per cent and is within the normal range. The mean blood sugar value for the 16
alloxan diabetic rats that failed to develop tumour metastases was 210 mg. per
cent and this value is comparable to the mean blood sugar value found for the
rats in group 1.
DISCUSSION
From the results of this investigation, it is apparent that alloxan diabetic rats
fare better than control rats in terms of rate of tumour growth and secondary
tumour development. Not only do solid tumours in an intra-muscular situation
grow more slowly in diabetic rats but diabetic rats also develop fewer pulmonary
metastases than non-diabetic, control, animals following the intravenous injection
of the same number of cancer cells.
This experimental study, however, throws no light on the mechanisms re-
sponsible for these observed results. The presence ofdiabetes in a tumour bearing
animal may retard solid tumour growth indirectly by depriving the developing
cancer of vital metabolites or the diabetic process may act directly on the cancer
cells, involving them in the metabolic abnormalities occurring elsewhere within the
host. The associated hyperglycaemia ofdiabetes may be of some protective value
in preventing the development of tumour metastases from circulating cancer cells.
It has been previously shown that if rats are made hyperglycaemic by the intra-
peritoneal injection of glucose before the intravenous injection of cancer cells,
then these animals will develop significantly fewer tumour metastases than rats
that have normal blood sugars at the time the tumour cells are introduced into the
circulation (Garvie, 1967).
Should the results of this experimental investigation be applicable to the
human situation, then patients with diabetes mellitus who develop malignant
disease should fare better in terms of survival than non-diabetic patients who
develop a similar cancer. However, certain factors require consideration.
Patients with established diabetes who develop malignant disease will be receiving
treatment for their diabetes and, although it is not known how such treatment will
influence the malignant process, it is to be anticipated that this therapy will make
the diabetic patient react to his malignant disease in a manner similar to the non-
diabetic patient. On the other hand, in both diabetes mellitus and cancer there
may be a considerable time interval between the inception of the disease and its
clinical recognition. From estimations based on epidemiological data Anderson
(1966) has shown that for persons in their forties and fifties the mean length of
time between the appearance of impaired carbohydrate tolerance and the time of
diagnosis of diabetes mellitus is at least 10-12 years. The period of undetected
growth for malignant tumours similarly spans many years (Schwartz, 1961). It is
apparent, therefore, that these two diseases can co-exist undiagnosed within the
same host for some considerable time and under these circumstances the diabetes
may have a modifying influence on the malignant process.
The tumour bearing rats also fare better with respect to their diabetes than the
non-tumour bearing, but diabetic, control animals. The results of this investiga-
tion show that the presence of a developing cancer within the diabetic host animal
has a modifying effect on the hyperglyeaemia ofthe diabetic process. Ingle (1960)
has found that in rats the glycosuria ofsteroid induced diabetes is suppressed ifthe
animals are made hosts to the Walker 256 tumour. He concluded that the im-
provement in the diabetic state could be attributed either to a non-specific toxic
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effectofthetumourongeneral metabolic activity orthatthetumourmightproduce
a more direct metabolic effect such as cortisone inactivation. However, in spite
offurther research into this problem thereason for the improvement inthe diabetic
state remains undetermined (Ingle, 1965).
The results of this investigation have shown that in rats the two disorders,
alloxan diabetes and cancer have a modifying influence on each other. The
human situation is currently being investigated to see if a similar relationship
between diabetes mellitus and cancer exists.
SUMMARY
The influence ofalloxan induced diabetes on tumour growth rate and secondary
tumour development has been estimated, using rats as the experimental animal.
It has been shown that not only does alloxan induced diabetes retard the rate of
tumour growth but also that it inhibits the development of metastases from
circulating cancer cells. The possible clinical significance of these findings are
discussed.
It was also found that the presence of a developing cancer in alloxan diabetic
rats had a modifying effect on the associated hyperglycaemia. The reason for
this improvement in the diabetic state is not known.
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